Based on the findings reported here, further studies should contemplate the possibility of a risk stratification in accordance with the SH2B1 genotyping once increasing the proportion of homozygous risk allele carriers in the study population in order to better assess the role of the polymorphism in NAFLD subjects. The gene discussed is SH2B1; the disease is metabolic dysfunction-associated steatotic liver disease.